NCT00435825View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

PHASE4CompletedINTERVENTIONAL
Enrollment

551

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Hepatitis B, Chronic
Interventions
DRUG

peginterferon alfa-2a [Pegasys]

90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.

Trial Locations (55)

100

Auckland

Taipei

333

Taoyuan District

807

Kaohsiung City

852

Hong Kong

3065

Fitzroy

4102

Woolloongabba

4120

Greenslopes

10400

Bangkok

10700

Bangkok

11355

Flushing

13353

Berlin

19141

Philadelphia

23249

Richmond

30306

Atlanta

30625

Hanover

31078

Toulouse

34295

Montpellier

40002

Khon Kaen

50202

Chiang Mai

50937

Cologne

60590

Frankfurt am Main

67091

Strasbourg

79106

Freiburg im Breisgau

90095

Los Angeles

90112

Songkhla

92105

San Diego

92118

Clichy

94115

San Francisco

94804

Villejuif

95116

San Jose

97227

Portland

100050

Beijing

100054

Beijing

169608

Singapore

190103

Saint Petersburg

200025

Shanghai

201508

Shanghai

214006

Smolensk

355017

Stavropol

410008

Hunan

443021

Samara

510630

Guangzhou

94304-1509

Palo Alto

13081-970

Campinas

14049-900

Ribeirão Preto

40150-130

Salvador

09060-650

Santo André

05403-000

São Paulo

06202

Nice

Unknown

Hong Kong

Hamilton

110-744

Seoul

120-752

Seoul

138-736

Seoul

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00435825 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). | Biotech Hunter | Biotech Hunter